192 related articles for article (PubMed ID: 21190039)
21. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.
Baruchel S; Pappo A; Krailo M; Baker KS; Wu B; Villaluna D; Lee-Scott M; Adamson PC; Blaney SM
Eur J Cancer; 2012 Mar; 48(4):579-85. PubMed ID: 22088484
[TBL] [Abstract][Full Text] [Related]
22. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
23. Improving the outcome for children with cancer: Development of targeted new agents.
Adamson PC
CA Cancer J Clin; 2015; 65(3):212-20. PubMed ID: 25754421
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor inhibition strategies in oncology.
Harari PM
Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
[TBL] [Abstract][Full Text] [Related]
25. Novel targeted therapies in acute lymphoblastic leukemia.
Portell CA; Advani AS
Leuk Lymphoma; 2014 Apr; 55(4):737-48. PubMed ID: 23841506
[TBL] [Abstract][Full Text] [Related]
26. Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada.
Judd S; Revon-Riviere G; Grover SA; Deyell RJ; Vanan MI; Lewis VA; Pecheux L; Zorzi AP; Goudie C; Santiago R; Tran TH; Abbott LS; Brossard J; Moorehead P; Alvi S; Portwine C; Denburg A; Whitlock JA; Cohen-Gogo S; Morgenstern DA
Cancer Med; 2024 Feb; 13(3):e7033. PubMed ID: 38400668
[TBL] [Abstract][Full Text] [Related]
27. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
Jabbour E; Pui CH; Kantarjian H
JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of anti-cancer action and pharmacology of clofarabine.
Zhenchuk A; Lotfi K; Juliusson G; Albertioni F
Biochem Pharmacol; 2009 Dec; 78(11):1351-9. PubMed ID: 19576186
[TBL] [Abstract][Full Text] [Related]
29. Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.
Minguet J; Smith KH; Bramlage P
Int J Cancer; 2016 Jun; 138(11):2549-61. PubMed ID: 26537995
[TBL] [Abstract][Full Text] [Related]
30. Targeted anti-cancer therapy in the elderly.
Gonsalves W; Ganti AK
Crit Rev Oncol Hematol; 2011 Jun; 78(3):227-42. PubMed ID: 20599391
[TBL] [Abstract][Full Text] [Related]
31. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.
Gharwan H; Groninger H
Nat Rev Clin Oncol; 2016 Apr; 13(4):209-27. PubMed ID: 26718105
[TBL] [Abstract][Full Text] [Related]
32. CD22 as a target for cancer therapy.
Tu X; LaVallee T; Lechleider R
J Exp Ther Oncol; 2011; 9(3):241-8. PubMed ID: 22070056
[TBL] [Abstract][Full Text] [Related]
33. Challenging issues in pediatric oncology.
Pui CH; Gajjar AJ; Kane JR; Qaddoumi IA; Pappo AS
Nat Rev Clin Oncol; 2011 Jun; 8(9):540-9. PubMed ID: 21709698
[TBL] [Abstract][Full Text] [Related]
34. Clofarabine.
Drugs R D; 2004; 5(4):213-7. PubMed ID: 15230627
[TBL] [Abstract][Full Text] [Related]
35. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Stegmaier K; Bourdeaut F; Reaman G; Heenen D; Meyers ML; Armstrong SA; Brown P; De Carvalho D; Jabado N; Marshall L; Rivera M; Smith M; Adamson PC; Barone A; Baumann C; Blackman S; Buenger V; Donoghue M; Duncan AD; Fox E; Gadbaw B; Hattersley M; Ho P; Jacobs I; Kelly MJ; Kieran M; Lesa G; Ligas F; Ludwinski D; McDonough J; Nikolova Z; Norga K; Senderowicz A; Taube T; Weiner S; Karres D; Vassal G
Eur J Cancer; 2020 Nov; 139():135-148. PubMed ID: 32992153
[TBL] [Abstract][Full Text] [Related]
36. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
Hojjat-Farsangi M
J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367
[TBL] [Abstract][Full Text] [Related]
37. Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology.
Molica S
Expert Rev Hematol; 2015 Jun; 8(3):277-81. PubMed ID: 25804936
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology.
Lorusso PM; Eder JP
Expert Opin Investig Drugs; 2008 Jul; 17(7):1013-28. PubMed ID: 18549338
[TBL] [Abstract][Full Text] [Related]
39. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
40. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
